Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.80 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.65 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.65 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.61 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245357 | 0.90 | CYP24A1 (0.80) | CYP19A1CYP24A1CYP26A1CYP27A1DRD2 | |
| SCHEMBL6825978 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL7784427 | 0.88 | CYP19A1 (0.62) | CYP19A1CYP24A1CYP26A1METAP1 | |
| SCHEMBL30667087 | 0.88 | CYP19A1 (0.62) | CYP19A1CYP24A1CYP26A1METAP1 | |
| SCHEMBL6827906 | 0.87 | CYP19A1 (0.76) | CYP19A1CYP24A1CYP26A1CYP27A1 | |
| SCHEMBL29679457 | 0.85 | CYP24A1 (0.66) | CYP19A1CYP24A1CYP26A1CYP27A1SIGMAR1 | |
| SCHEMBL15874727 | 0.85 | CYP24A1 (0.66) | CYP19A1CYP24A1CYP26A1CYP27A1SIGMAR1 | |
| SCHEMBL7244157 | 0.85 | CYP24A1 (0.66) | CYP19A1CYP24A1CYP26A1CYP27A1SIGMAR1 | |
| SCHEMBL28733982 | 0.85 | CYP24A1 (0.66) | CYP19A1CYP24A1CYP26A1CYP27A1SIGMAR1 | |
| SCHEMBL7243310 | 0.85 | CYP24A1 (0.60) | CYP19A1CYP24A1CYP26A1CYP27A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
| US-5998451-A | LIPOXYGENASE INHIBITORS | PFIZER INC (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0313295-B1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA, ARTHRITIS AND RELATED DISEASES | PFIZER INC. (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5059609-A | Lipoxygenase inhibitors; leukotriene receptor blockers; psoriasis; antiulcer agents and myocardial infarctions | PFIZER INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0313295-A2 | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases | PFIZER INC. (US) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | CYP19A1 2314/4885CYP24A1 1214/4885CYP26A1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.